Skip to content

Aidoc and the EU AI Act: Medical-Imaging Triage Takes the Product Route, Not Annex III

AI Tool Compliance4 November 2026· 8 min read

Aidoc's radiology triage AI is high-risk via the EU AI Act Annex I product route under MDR: integrated conformity, 2 August 2028 deadline, not Annex III.

High-risk — but by the product route, not the self-assessment route most people assume. Aidoc's clinical AI triages radiology studies: it reviews CT and other scans, flags acute findings (intracranial haemorrhage, pulmonary embolism, abdominal injuries and more), and reprioritises the worklist so suspected emergencies move up the radiologist's queue. Because it analyses medical images to support clinical decisions, it is software that qualifies as a medical device, CE-marked under the Medical Device Regulation (EU) 2017/745 (MDR). That routing is what decides its EU AI Act treatment.

Under Article 6(1) of Regulation (EU) 2024/1689, an AI system that is a safety component of, or is itself, a product covered by the Union harmonisation legislation listed in Annex I — which includes the MDR — and that must undergo a third-party conformity assessment under that legislation, is high-risk. So Aidoc is high-risk via the Annex I product route: conformity is integrated into the MDR assessment a notified body already performs, and the deadline is 2 August 2028 — not the 2 December 2027 self-assessment route that applies to stand-alone Annex III systems.

This is a deployer-side playbook for hospitals. For the use-case doctrine see medical-imaging AI under the EU AI Act and healthcare AI and medical devices.


Why Aidoc is high-risk by the product route (Article 6(1))

There are two doors into the high-risk regime, and a medical-imaging triage tool goes through the first.

Article 6(1) — the product route. A system is high-risk if it is a product, or the safety component of a product, covered by the Annex I harmonisation legislation and required to undergo third-party conformity assessment under that legislation. The MDR (Regulation (EU) 2017/745) is in Annex I, Section A. Aidoc's triage software is a medical device that, at its risk class, undergoes notified-body conformity assessment under the MDR. That is the Article 6(1) trigger.

Article 6(2) — the Annex III route. This is the other door: stand-alone systems used for one of the eight Annex III high-risk areas, self-assessed via Annex VI internal control (or, for biometrics, the notified-body Annex VII route). Medical-imaging triage does not go through this door. Annex III does not list general healthcare diagnostics as a stand-alone area; the medical-device character pulls it into Article 6(1) instead. Treating Aidoc as an Annex III self-assessment system is the common error this page exists to correct.

The practical consequence: the EU AI Act's high-risk requirements (risk management, data governance, technical documentation, human oversight, accuracy and robustness) are integrated into the MDR conformity assessment rather than run as a separate AI Act process. One conformity assessment, performed by the MDR notified body, carrying both sets of requirements.


Integrated conformity: what "the product route" means in practice

For a stand-alone Annex III system, the provider runs the AI Act conformity assessment itself (Annex VI) and registers in the EU database. For an Annex I product-route system, that machinery is folded into the sectoral regime:

  • The conformity assessment (Article 43) is carried out within the MDR procedure, by the notified body already assessing the device — not as a separate AI Act exercise.
  • The AI Act's high-risk requirements (Articles 9-15) must be satisfied, but they are demonstrated through the MDR technical documentation and quality-management system, not a parallel AI Act dossier.
  • CE marking and the declaration of conformity are the MDR ones, now also evidencing AI Act conformity.
  • Aidoc's role as the manufacturer maps to provider under the AI Act; the hospital running it is the deployer.

This integration is the point of Article 6(1): a medical-device manufacturer should not face two disconnected conformity regimes for the same product.


Who does what: hospital deployer vs Aidoc provider

RoleWhoCore duties
ProviderAidoc (device manufacturer)MDR conformity assessment incorporating AI Act Articles 9-15; technical documentation; CE marking; post-market surveillance; serious-incident reporting
DeployerThe hospital / radiology departmentUse per instructions for use; ensure radiologist human oversight (Art 14 / 26); maintain logs; AI literacy (Art 4); cooperate with monitoring

The hospital's duties as deployer (Article 26) are the ones a radiology department must own. Use Aidoc in line with its instructions for use. Assign human oversight (Article 14): triage flags and reprioritises, but a qualified radiologist makes and signs the diagnosis — the AI must not replace the human read. Keep the logs the system generates, and feed any malfunction or near-miss back to Aidoc and, where relevant, the authorities. Deliver Article 4 AI literacy (already in force) to the radiologists and technologists who rely on it. A public hospital does not owe an Article 27 FRIA here: that duty covers only Article 6(2) Annex III systems, not Article 6(1) product-route devices like Aidoc.

Critically, triage is decision support, not decision replacement. The human-oversight duty is what keeps a missed or mis-prioritised flag from becoming an unreviewed clinical error — the radiologist still reads every study.


The deadline: 2 August 2028

Annex I product-embedded high-risk systems apply from 2 August 2028 under the Digital Omnibus — eight months later than the stand-alone Annex III date, reflecting the integration work with the sectoral regimes.

Keep the two tracks distinct: stand-alone Annex III high-risk (Article 6(2)) applies from 2 December 2027; Annex I product-embedded high-risk (Article 6(1)), which is where Aidoc sits, applies from 2 August 2028.

Freshness note: the Digital Omnibus — Regulation (EU) 2026/1744, published in the Official Journal on 24 July 2026 and in force since 27 July 2026 — set the Annex I product route deadline at 2 August 2028, moved from the original 2 August 2027. The MDR obligations themselves are already fully in force and independent of this timeline — Aidoc must hold valid MDR CE marking now.


Penalties

BreachMaximum fineParagraph
High-risk requirements / deployer obligations€15,000,000 or 3% of worldwide annual turnover, whichever is higherArticle 99(4)
Prohibited practices (Article 5) - not relevant here€35,000,000 or 7%Article 99(3)
Incorrect or misleading information to a notified body or authority€7,500,000 or 1%Article 99(5)
SME / start-up capThe lower of the percentage or the fixed amountArticle 99(6)

An AI Act high-risk or deployer breach is an Article 99(4) matter — up to €15 million or 3%. The €35 million / 7% tier is reserved for Article 5 prohibited practices and is not in play for a diagnostic-support device. The third tier is 1%, never 1.5%, and bites where incorrect or misleading information is given to a notified body or authority — a real exposure in the medical-device context. These EU AI Act penalties sit alongside, not instead of, the MDR's own enforcement regime; a hospital faces both frameworks.


Worked example: Sankt-Gregor Klinikum, ~1,400 staff, ~€190M turnover

Sankt-Gregor Klinikum, a regional German hospital group with around 1,400 staff and roughly €190 million turnover, deploys Aidoc in its emergency radiology workflow: CT studies are auto-triaged, suspected strokes and pulmonary emboli jump the queue, and the on-call radiologist reads the prioritised list.

Aidoc is the provider (the MDR device manufacturer); Sankt-Gregor is the deployer. This is an Article 6(1) product-route high-risk system, not an Annex III self-assessment one. The hospital's action list:

  • Confirm Aidoc holds valid MDR CE marking and obtain the instructions for use and AI Act conformity evidence (integrated in the MDR dossier).
  • Assign and document radiologist human oversight: triage prioritises, the radiologist diagnoses (Articles 14 and 26).
  • Retain the system logs and route malfunctions and near-misses back to Aidoc.
  • Deliver Article 4 AI literacy to radiology staff.
  • Record that no Article 27 FRIA is owed: Aidoc is a product-route system, and the FRIA covers only Annex III systems.
  • Track both the MDR timeline (already live) and the AI Act product-route date (2 August 2028, originally 2 August 2027 before Regulation (EU) 2026/1744).

The hospital does not run a separate Annex III conformity assessment — that is the manufacturer's MDR-integrated process. Its job is correct, oversight-driven deployment.


How Confir helps

Register Aidoc in your AI inventory and Confir's deterministic, rule-based classification engine routes it correctly — recognising the medical-device character that sends it down the Article 6(1) product route via the MDR, not the Annex III self-assessment path, with the 2 August 2028 deadline. It captures the hospital's Article 26 deployer duties — human oversight, logging and literacy, with no FRIA for a product-route system — and records an auditable finding with the rule that fired in plain language. Same intake, same result, no model inference.


Manage your EU AI Act compliance in one place

Confir automates risk classification, technical documentation, and audit trails for any company. No consultants. No 6-month projects. 14-day free trial.

Start free trial →